NAMSW | NewAmsterdam Pharma Company N.V. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	6.49 - 6.71
52 Week Range	0.9900 - 14.67
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	203
Average Volume	4,141
Shares Outstanding	216,788,102
Market Cap	1,406,954,782
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-10

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	57
Country	Netherlands
Website	NAMSW

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

NAMSW's peers: CNTA, STRO, HLVX, PMN, NWTNW, NAMS, SCLXW, GRNAW, OABIW, ROIVW, EUDAW, ECXWW, COYA

*Chart delayed

Analyzing fundamentals for NAMSW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see NAMSW Fundamentals page.

Watching at NAMSW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NAMSW Technicals page.